Back
Editas Medicine Quote, Financials, Valuation and Earnings
Sponsored
EDIT
Sponsored
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
43
EDIT
Editas Medicine
Last Price:
2.67
Seasonality Move:
16.26%
7 Day Trial
ALL ACCESS PASS
$
7
Buy these stocks BEFORE President Trump returns to the Oval Office
See details on which stocks are poised to surge.Editas Medicine Price Quote
$2.67
-0.10 (-3.61%)
(Updated: November 15, 2024 at 5:55 PM ET)
Editas Medicine Key Stats
Sell
43
Editas Medicine (EDIT)
is a Sell
Day range:
$2.76 - $2.98
52-week range:
$2.70 - $11.69
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.68
P/B ratio:
1.3%
Volume:
1.7M
Avg. volume:
2.1M
1-year change:
-67.49%
Market cap:
$228.7M
Revenue:
$78.1M
EPS:
$-2.56
How Much Does Editas Medicine Make?
-
How Much Are Editas Medicine's Sales Annually?
EDIT Revenues are $78.1M -
How Much Profit Does Editas Medicine's Make A Year?
EDIT net income is -$153.2M
Is Editas Medicine Growing As A Company?
-
What Is Editas Medicine's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.99% -
What Is Editas Medicine's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Editas Medicine Stock Price Performance
-
Did Editas Medicine Stock Go Up Last Month?
Editas Medicine share price went down by -14.51% last month -
Did EDIT's Share Price Rise Over The Last Year?
EDIT share price fell by -67.49% over the past 1 year
What Is Editas Medicine 52-Week High & Low?
-
What Is Editas Medicine’s 52-Week High Share Price?
Editas Medicine has traded as high as $11.69 over the past 52 weeks -
What Is Editas Medicine’s 52-Week Low Share Price?
Editas Medicine has traded as low as $2.70 over the past 52 weeks
Editas Medicine Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Editas Medicine?
-
How Much Debt Does Editas Medicine Have?
Total long term debt quarterly is $0 -
How Much Cash Does Editas Medicine Have?
Cash and short term investments quarterly total is $265.1M -
What Is Editas Medicine’s Book Value Per Share?
Book value per share is 2.13
Is Editas Medicine Cash Flow Positive?
-
What Is EDIT Cash Flow From Operations?
Cash flow from operations (TTM) is -$181.8M -
What Is Editas Medicine’s Cash Flow From Financing?
Cash flow from financing (TTM) is $1M -
What Is Editas Medicine’s Cash Flow From Investing?
Cash flow from investing (TTM) is $194M
Editas Medicine Return On Invested Capital
-
Is Management Doing A Good Job?
EDIT return on invested capital is -74.59% -
What Is Editas Medicine Return On Assets?
ROA measures how assets are converting to revenues and is -48.82% -
What Is EDIT Return On Equity?
ROE is a measure of profitability and is -74.59%
Editas Medicine Earnings Date & Stock Price
-
What Is Editas Medicine's Stock Price Today?
A single share of EDIT can be purchased today for 2.77 -
What Is Editas Medicine’s Stock Symbol?
Editas Medicine trades on the nasdaq under the ticker symbol: EDIT -
When Is Editas Medicine’s Next Earnings Date?
The next quarterly earnings date for Editas Medicine is scheduled on February 28, 2025 -
When Is EDIT's next ex-dividend date?
Editas Medicine's next ex-dividend date is November 16, 2024 -
How To Buy Editas Medicine Stock?
You can buy Editas Medicine shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Editas Medicine Competitors
-
Who Are Editas Medicine's Competitors?
Below is a list of companies who compete with Editas Medicine or are related in some way:
Editas Medicine Dividend Yield
-
What Is EDIT Dividend Yield?
Editas Medicine’s dividend yield currently is 0% -
What Is Editas Medicine’s Payout Ratio?
Editas Medicine’s payout ratio is 0% -
When Did Editas Medicine Last Pay A Dividend?
The latest dividend pay date is November 16, 2024 -
What Is Editas Medicine’s Dividend Per Share?
Editas Medicine pays a dividend of $0.00 per share
Editas Medicine Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 2.53% |
Revenue: | -98.86% | -98.43% |
Analyst Recommendations
Buy Recommendations: | 10 |
---|---|
Hold Recommendations: | 9 |
Sell Recommendations: | 0 |
Price Target: | 9.07 |
Upside from Last Price: | 227.49% |